Self-assembled aggregation-induced emission nanoprobes for targeted therapy and real-time imaging of non-small cell lung cancer and application thereof
The self-assembled aggregation-induced emission nanoprobes (AIEnps) have enabled precise diagnosis and targeted therapy for non-small cell lung cancer, solving the problems of poor tumor penetration and drug resistance, and achieving the dual functions of real-time imaging and c-Met inhibition.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- THE AFFILIATED CENT HOSPITAL OF DALIAN UNIV OF TECH (DALIAN CENT HOSPITAL)
- Filing Date
- 2025-10-30
- Publication Date
- 2026-06-09
AI Technical Summary
Existing technologies for the treatment of non-small cell lung cancer (NSCLC) suffer from poor tumor penetration, non-specific distribution, and drug resistance, making it difficult to achieve precise real-time tumor localization and effective targeted therapy.
We developed self-assembled aggregation-induced emission nanoprobes (AIEnps) that combine c-Met targeting sequences and microenvironment response design to achieve specific accumulation and fluorescence tracking of nanomaterials at tumor sites. By combining c-Met inhibitor functions, we can achieve targeted therapy and real-time imaging.
It effectively overcomes the problems of tumor penetration and non-specific distribution of traditional nanomedicines, enhances tumor targeting ability, realizes precise diagnosis and treatment of tumors and inhibits c-Met-mediated tumor growth, and reduces drug resistance.
Smart Images

Figure CN121362262B_ABST